Studies of Drug-Induced Birth Defects

Pharmacoepidemiology, Fourth Edition

Volumn , Issue , 2007, Pages 501-514

  Mitchell, Allen A ^a,b  

^a BOSTON UNIVERSITY   (United States)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

"class action" teratogenesis fallacy; Biologic plausibility in drug defect associations; Case control surveillance and drug induced birth defects; Drug induced birth defect; Maternal rubella infection in pregnancy; Non prescription (or over the counter, OTC) drugs; specific birth defect and sample size requirement; System for Thalidomide Education and Prescribing Safety (STEPS); Teratogenesis adverse drug effect

Indexed keywords

EID: 84889294771     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470059876.ch32     Document Type: Chapter

References (66)

1. Heinonen OP, Slone D, Shapiro S. The women, their offspring, and the malformations. In: Kaufman DW, ed., Birth Defects and Drugs in Pregnancy. Littleton, MA: Publishing Sciences Group, 1977; pp. 30-32.
2. CDC. Congenital Malformations Surveillance Report: January 1982-December 1985. Atlanta, GA: US Department of Health and Human Services, Public Health Service, 1988.
3. Gregg NM. Congenital cataract following German measles in the mother. Trans Ophthalmol Soc Aust 1941; 3: 35-46.
4. Lenz W. Thalidomide and congenital abnormalities. Lancet 1962; 1: 45.
5. Warkany J. Problems in applying teratologic observations in animals to man. Pediatrics 1974; 53: 820.
6. Mitchell AA. Systematic identification of drugs that cause birth defects-a new opportunity. N Engl J Med 2003; 349: 2556-9.
7. Stern RS. When a uniquely effective drug is teratogenic: the case of isotreninoin. N Engl J Med 1989; 320: 1007-9.
8. Mitchell AA, Van Bennekom C, Louik C. A pregnancyprevention program in women of childbearing age receiving isotretinoin. N Engl J Med 1995; 333: 101-6.
9. Mitchell AA, Van Bennekom C. Isotretinoin Survey. Presentation at FDA Advisory Committees. Gaithersburg, MD, February 26, 2004.
10. Holmes LB. Teratogen update: Bendectin. Teratology 1983; 27: 277-81.
11. Neutel CI, Johansen HL. Measuring drug effectiveness by default: the case of Bendectin. Can J Pub Health 1995; 86:66-70.
12. Hook EB, Healy KB. Consequences of a nationwide ban on spray adhesives alleged to be human teratogens and mutagens. Science 1976; 191: 566-7.
13. Heinonen OP, Slone D, Shapiro S. Sedatives, tranquilizers, and antidepressant drugs. In: Kaufman DW, ed., Birth Defects and Drugs in Pregnancy. Littleton, MA: Publishing Sciences Group, 1977; pp. 335-44.
14. Newman CGH. Teratogen update: clinical aspects of thalidomide embryopathy-a continuing preoccupation. Teratology 1985; 32: 133-44.
15. Lammer EJ, Chen DT, Hoar RM, Agnish ND, Benke PJ, Braun JT et al. Retinoic acid embryopathy. N Engl J Med 1985; 313: 837-41.
16. Robert E. [Example of teratogen detection using a birth defects registry: depakine and spina bifida.] Rev Epidemiol Sante Publique 1996; 44 (suppl 1): 78-81 (in French).
17. Whitfield MF. Chondrodysplasia punctata after warfarin in early pregnancy. Arch Dis Child 1980; 55: 139-42.
18. Martin RA, Jones KL, Mendoza A, Barr M, Benirschke K. Effect of ACE inhibition on the fetal kidney: decreased renal blood flow. Teratology 1992; 46: 317-21.
19. Werler MM, Mitchell AA, Shapiro S. First trimester maternal medication use in relation to gastroschisis. Teratology 1992; 45: 361-7.
20. Rayburn W, Wible-Kant J, Bledsoe P. Changing trends in drug use during pregnancy. J Reprod Med 1982; 27: 569-75.
21. Mitchell AA, Hernandez-Diaz S, Louik C, Werler MM. Medication use in pregnancy, 1976-2000. Pharmacoepidemiol Drug Saf 2001; 10: S146.
22. Louik C, Werler MM, Hernandez-Diaz S, Mitchell AA. Use of herbal treatments in pregnancy. Pharmacoepidemiol Drug Saf 2003; 12: S113.
23. Mitchell AA, Cottler LB, Shapiro S. Effect of questionnaire design on recall of drug exposure in pregnancy. Am J Epidemiol 1986; 123: 670-6.
24. Werler MM, Pober BR, Nelson K, Holmes LB. Reporting accuracy among mothers of malformed and nonmalformed infants. Am J Epidemiol 1989; 129: 415-21.
25. Rothman KJ, Fyler DC, Goldblatt A, Kreidberg MB. Exogenous hormones and other exposures of children with congenital heart disease. Am J Epidemiol 1979; 109: 433-9.
26. Bingol N, Fuchs M, Diaz V, Stone RK, Gromisch DS. Teratogenicity of cocaine in humans. J Pediatr 1987; 110: 93-6.
27. Mitchell AA, Rosenberg L, Shapiro S, Slone D. Birth defects related to Bendectin use in pregnancy. 1. Oral clefts and cardiac defects. JAMA 1981; 245: 2311-14.
28. Slutsker L. Risks associated with cocaine use during pregnancy. Obstet Gynecol 1992; 79: 778-89.
29. Bracken MB. Methodologic issues in the epidemiological investigation of drug-induced congenital malformations. In: Bracken MB, ed., Perinatal Epidemiology. New York: Oxford University Press, 1984.
30. Mills JL, Rhoads GG, Simpson JL, Cunningham GC, Conley MR, Lassman MR et al. The absence of a relation between the periconceptional use of vitamins and neural tube defects. N Engl J Med 1989; 321: 430-5.
31. Werler MM, Shapiro S, Mitchell AA. Periconceptional folic acid exposure and risk of occurrent neural tube defects. JAMA 1993; 269: 1257-61.
32. Johnston MC, Sulik KK. Some abnormal patterns of development in the craniofacial region. Birth Defects Orig Artic Ser 1979; 15: 23-42.
33. Hoyme HE, Jones MC, Jones KL. Gastroschisis: abdominal wall disruption secondary to early gestational interruption of the omphalomesenteric artery. Semin Perinatol 1983; 7: 294-8.
34. Werler MM, Sheehan JE, Mitchell AA. Association of vasoconstrictive exposures with risks of gastroschisis and small intestinal atresia. Epidemiology 2003; 14: 349-54.
35. Khoury MJ, Moore CA, James LM, Cordero JF. The interaction between dysmorphology and epidemiology: methodologic issues of grouping and splitting. Teratology 1992; 45: 133-8.
36. Slone D, Shapiro S, Miettinen OS, Finkle WD, Stolley PD. Drug evaluation after marketing. Ann Intern Med 1979; 90: 257-61.
37. MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet 1991; 338: 131-7.
38. Hernandez-Diaz S, Werler MM, Walker AM, Mitchell AA. Neural tube defects in relation to use of folic acid antagonists during pregnancy. Am J Epidemiol 2001; 153: 961-8.
39. Martinez-Frias ML, Rodriguez-Pinilla E, Prieto L. Prenatal exposure to salicylates and gastroschisis: a case-control study. Teratology 1997; 56: 241-3.
40. Werler MM, Sheehan JE, Mitchell AA. Maternal medication use and risks of gastroschisis and small intestinal atresia. Am J Epidemiol 2002; 155: 26-31.
41. Khoury MJ, Holtzman NA. On the ability of birth defects monitoring to detect new teratogens. Am J Epidemiol 1987; 126: 136-43.
42. Michaelis J, Gluck E, Michaelis H, Koller S, Degenhardt K-H. Teratogene Effekte von Lenotan. Dtsch Arztebl 1980; 23: 1527-9.
43. Gibson GT, Colley DP, McMichael AJ, Hartshorne JM. Congenital anomalies in relation to the use of doxylamine/dicyclomine and other antenatal factors. Med J Aust 1981; 1: 410-14.
44. Harlap S, Shiono PH, Ramcharan S, Golbus M, Bachman R, Mann J, Lewis JP. Chromosomal abnormalities in the Kaiser-Permanente Birth Defects Study, with special reference to contraceptive use around the time of conception. Teratology 1985;31: 381-7.
45. Czeizel A. Lack of evidence of teratogenicity of benzodiazepine drugs in Hungary. Reprod Toxicol 1988; 1: 183-8.
46. Olsen J. Experiences from an existing birth cohort: the Danish National Birth Cohort. Presentation at Medicines Exposures Workshop (National Children's Study). Baltimore, MD,December 16, 2002.
47. Slone D, Siskind V, Heinonen OP, Monson RR, Kaufman DW, Shapiro S. Aspirin and congenital malformations. Lancet 1976; 1: 1373-5.
48. Jick H, Holmes LB, Hunter JR, Madsen S, Stergachis A. Firsttrimester drug use and congenital disorders. JAMA 1981; 246: 343-6.
49. Jick SS, Terris BZ, Jick H. First trimester topical tretinoin and congenital disorders. Lancet 1993; 341: 1181-2.
50. Bergman U, Rosa FW, Baum C, Wiholm B-E, Faich GA. Effects of exposure to benzodiazepine during fetal life. Lancet 1992; 340: 694-6.
51. Ratanajamit C, Skriver MV, Norgaard M, Jepsen P, Schonheyder HC, Sorensen HT. Adverse pregnancy outcome in users of sulfamethizole during pregnancy: a populationbased observational study. J Antimicrob Chemother 2003; 52: 837-41.
52. FDA. Guidance for industry: Establishing pregnancy exposure registries. Available at: http://www.fda.gov/cder/guidance/3626fnl.pdf.
53. Dai WS, LaBraico JM, Stern RS. Epidemiology of isotretinoin exposure during pregnancy. J Am Acad Dermatol 1992; 26: 599-606.
54. Chambers C, Braddock SR, Briggs GG, Einarson A, Johnson YR, Miller RK et al. Postmarketing surveillance for human teratogenicity: a model approach. Teratology 2001; 64: 252-61.
55. St Clair SM, Schirmer RG. First-trimester exposure to alprazolam. Obstet Gynecol 1992; 80: 843-6.
56. Pastuszak A, Schick-Boschetto B, Zuber C, Feldkamp M, Pinelli M, Sihn S et al. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA 1993; 269: 2246-8.
57. Yoon PW, Rasmussen SA, Lynberg MC, Moore CA, Anderka M, Carmichael SL et al. The national birth defects prevention study. Public Health Rep 2001; 116 (suppl 1): 32-40.
58. Jick H, Walker AM, Rothman KJ, Hunter JR, Holmes LB, Watkins RN et al. Vaginal spermicides and congenital disorders. JAMA 1981; 245: 1329-32.
59. Mills JL, Harley EE, Reed GF, Berendes HW. Are spermicides teratogenic? JAMA 1982; 248: 2148-51.
60. Shapiro S, Slone D, Heinonen OP, Kaufman DW, Rosenberg L, Mitchell AA et al. Birth defects and vaginal spermicides.JAMA 1982; 247: 2381-84.
61. Louik C, Mitchell AA, Werler MM, Hanson JW, Shapiro S. Maternal exposure to spermicides in relation to certain birth defects. N Engl J Med 1987; 317: 474-8.
62. Warburton D, Neugut RH, Lustenberger A, Nicholas A, Kline J. Lack of association between spermicide use and trisomy. N Engl J Med 1987; 317: 478-82.
63. Ostrea EM Jr, Romero A, Yee H. Adaptation of the meconium drug test for mass screening. J Pediatr 1993; 122: 152-4.
64. Graham K, Koren G, Klein J, Schneiderman J, Greenwald M. Determination of gestational cocaine exposure by hair analysis.JAMA 1989; 262: 3328-30.
65. Strickler SM, Dansky LV, Miller MA, Seni MH, Andermann E, Spielberg SP. Genetic predisposition to phenytoin-induced birth defects. Lancet 1985; 2: 746-9.
66. Andrews EB, International Society for Pharmacoepidemiology. Data privacy, medical record confidentiality, and research in the interest of public health. Pharmacoepidemiol Drug Saf 1999; 8: 247-60.